Ozay, Z. I., Jo, Y., Gebrael, G., Nandakumar, V., Chehade, C. H., Lin, E., Ji, R., Ostrowski, M., Sayegh, N., Campbell, P., Garg, D., Revillo, R., Thomas, V. M., Gupta, S., Agarwal, N., Swami, U. (2026). Real-world survival outcomes with single-agent erdafitinib (Erda) in patients (pts) with advanced urothelial carcinoma (aUC) based on line (L) of therapy and prior enfortumab vedotin (EV) treatment (Rx).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.694